Recurrent Bilateral Chronic Central Serous Chorioretinopathy Treated with Anti-VEGF

Authors

  • Siti Mutia Atisundara Fakultas Kedokteran Universitas Padjadjaran, Sumedang, Indonesia
  • Erwin Iskandar Fakultas Kedokteran Universitas Padjadjaran, Sumedang, Indonesia / Rumah Sakit Mata Cicendo, Bandung, Indonesia

DOI:

https://doi.org/10.11594/ojkmi.v6i2.67

Keywords:

anti-VEGF, bilateral CSC, OCT

Abstract

Introduction: After diabetic retinopathy, branch retinal vein occlusion, and age-related macular degeneration, central serous chorioretinopathy (CSC) is the fourth most frequent retinopathy. Males in their 20s to 50s who have acute or subacute central vision loss or distortion are usually the ones who develop CSC, males more than females. Localized serous macula detachment is its defining feature. Within three to six months, the majority of instances resolve on their own and return to normal vision, but in certain situations, laser or medication treatment may be necessary.

Case: A 45-year-old male came with a chief complaint of gradually blurred vision in his right eye since a month ago. Optical computed tomography (OCT) examination showed an accumulation of sub-retinal fluid (SRF) suggestive of CSC. His visual acuity was declining even after being given oral spironolactone for 1 month, so he was scheduled for intravitreal injection Anti-Vascular Endothelial Growth Factor Therapy (Anti-VEGF). After three times in injection right eye the visual acuity improved. One month later he had a chief complaint of gradually blurred vision in his left eye. After three times in injection left eye, CSC in both eyes resolved and the visual acuity improved. Three years later he came back with a chief complaint on both eyes like three years ago.

Conclusion: Normally resolution of symptoms from CSC takes several months, treatment with anti- VEGF injection an efficient way to treat CSC resolution time and improve vision.

Downloads

Download data is not yet available.

References

Kim SJ, Fawzi A, Kovach JL, Patel S, Recchia FM, Sobrin L, et al. 2022- 2023 Basic and Clinical Science Course, Section 12: Retina and Vitreous. In: Basic and Clinical Science Course. San Francisco; 2022. p. 215–21.

Sadda SR., Sarraf D., Freund K.B., Hinton DR., Scachat A.P., Wilkinson C.P., et al. RYAN’S RETINA Section 3: Choroidal vascular. ELSEVIER. Los Angeles; 2022. p. 1530-49

Gupta A, Tripathy K. Central Serous Chorioretinopathy. Statpearls NCBI Books. August 2022. 55:1-21

Hanumunthadu, Daren, Tan, Anna C S; Singh, Sumit Randhir; Sahu, Niroj Kumar; Chhablani, Jay. Management of Chronic Central Serous Chorioretinopathy. Indian Journal of ophthalmology. 2018;66(12):1704-1714

Van Rijssen TJ, van Dijk EHC, Yzer S, Ohno-Matsui K, Keunen JEE, Schlingemann RO, et al. Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Progress in Retinal and Eye Research. 2019 Nov;73:100770.

Semeraro F, Morescalchi F, Russo A, Gambicorti E, Pilotto A, Parmeggiani F, et al. Central Serous Chorioretinopathy: Pathogenesis and Management. OPTH. 2019 Dec;Volume 13:2341–52.

Kido A, Miyake M, Tamura H, Hiragi S, Kimura T, Ohtera S, et al. Incidence of central serous chorioretinopathy (2011–2018): a nationwide population-based cohort study of Japan. Br J Ophthalmol. 2021 Jul 14; 319403: 74-9.

Alwassia AA, Adhi M, Duker JS. Bilateral simultaneous central serous chorioretinopathy in a teenage girl with systemic arterial hypertension. Int Ophthalmol. 2018 Feb;33(1):79–82.

Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Experiment Ophthalmol. 2018;41(2):201-141.

Gonçalves AN, Scott IU, Jorge R. Alternative management of central serous chorioretinopathy using intravitreal metoprolol. Int J Retin Vitr. 2022 Dec;8(1):50.

Zhang Y, Zhang J, Sun X. The Efficacy of Anti-VEGF Therapy for Putative or Visible CNV in Central Serous Chorioretinopathy by Optical Coherence Tomography Angiography. Ahmadieh H, editor. Journal of Ophthalmology. 2022 Sep 28;2022:1–11.

Ji S, Wei Y, Chen J, Tang S. Clinical efficacy of anti-VEGF medications for central serous chorioretinopathy: a meta-analysis. Int J Clin Pharm. 2017 Jun;39(3):514–21.

Ammar Fardhana, Ansyori A, Amin R. Diagnosis and Management of Central Serous Chorioretinopathy. sjo. 2020 Jun 20;3(1):44–50

Mohabati D, Boon CJ, Yzer S. Risk of Recurrence and Transition to Chronic Disease in Acute Central Serous Chorioretinopathy. OPTH. 2020 Apr;Volume 14:1165–75.

Sartini F, Figus M, Nardi M, Casini G, Posarelli C. Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options. Eye. 2019 Jul;33(7):1035–43.

Downloads

Submitted

16-04-2024

Accepted

30-08-2024

Published

30-08-2024

How to Cite

Atisundara, S. M., & Iskandar, E. (2024). Recurrent Bilateral Chronic Central Serous Chorioretinopathy Treated with Anti-VEGF. Oftalmologi Jurnal Kesehatan Mata Indonesia, 6(2), 42–48. https://doi.org/10.11594/ojkmi.v6i2.67

Most read articles by the same author(s)